arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Zoetis Inc.

ZTS
$82.16 ▼ -7.00 (-7.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
68
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

Zoetis Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $34.3B
Dividend Yield 0.65%
Revenue Growth 0.3% ↘
Op. Margin —
ROIC —
FCF / Share $1.29 ↗
Trailing P/E 49.8x
Price / Book 10.8x
FCF Yield 1.6%
Debt / Equity 2.87
info Valuation on last close. End-of-day price, Nov 5, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.47B
— +0.3% —
Net Income Profit after all expenses
$691.00M
↓ -3.8% —
FCF / Share Free cash flow per share
$1.29
↑ +86.9% —
Long-Term Debt Long-term obligations
$9.05B
— 0.0% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↑
88
Returns ↑
99
Financial Health ↑
9
Cash Quality →
58

Dividend History

Dividend / share · sourced from SEC filings
$2.03 Latest / share
+13.0% YoY
+20.3% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 57 quarters